Abstract
Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.
Original language | English (US) |
---|---|
Pages (from-to) | 1797-1799 |
Number of pages | 3 |
Journal | AIDS |
Volume | 33 |
Issue number | 11 |
DOIs | |
State | Published - Sep 1 2019 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases